Skip to content
OpenCapital
Get started

Bicara Therapeutics BCAX Unrealized gains (losses) on available-for-sale securities

Unrealized gains (losses) on available-for-sale securities at other companies

ArriVent BioPharma, Inc. logo
ArriVent BioPharma, Inc.AVBP
-$284K-246%
Erasca, Inc. logo
Erasca, Inc.ERAS
-$1.33M-695%

Other financials

Income statement

See full
Operating income-$60.2M-44.2%
Net income-$56.2M-52.6%
EPS (diluted)-$0.93-36.8%

Balance sheet

See full
Cash & equivalents$323.5M-30.0%
Total debt$1.4M+144%
Total equity$514.0M+12.0%
Total assets$553.6M+15.8%

Cash flow

See full
Operating cash flow-$37.5M-33.5%
CapEx$60.0K—
Free cash flow-$37.6M-33.7%

Valuation

See full
Market cap$1.68B+81.4%

Returns & leverage

See full
Return on equity-32.3%—
Debt / equity0×0.0×
Current ratio13.9×-10.8×

Where this comes from

Reported directly by Bicara Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax.

The official record: Bicara Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bicara Therapeutics's unrealized gains (losses) on available-for-sale securities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bicara Therapeutics's unrealized gains (losses) on available-for-sale securities?
Bicara Therapeutics (BCAX) reported unrealized gains (losses) on available-for-sale securities of -$486K in Q1 2026.
What does unrealized gains (losses) on available-for-sale securities mean?
The aggregate unrealized gains or losses on investment securities categorized as available-for-sale, recognized within comprehensive income. This reflects the market sensitivity of the company's treasury or investment portfolio. Investors use this to evaluate the risk profile of the company's idle cash and investment strategy.